Literature DB >> 21840597

Meta-analysis of human leukocyte antigen genetic polymorphisms and susceptibility to chronic myelogenous leukemia in Chinese population.

Min-Yue Zhang1, Fang-Yuan Chen, Hua Zhong.   

Abstract

Human leukocyte antigen (HLA) genetic polymorphisms are assumed to be correlated to the risk of chronic myelogenous leukemia (CML) in various ethnicities. Up to now, no clear consensus has been reached. Our goal is to address this issue in Chinese population. By searching the data in PubMed, Embase and four Chinese databases (prior to July 2010), the association of HLA genetic polymorphisms with CML has been fixed as the research objective. We studied a totality of 12 studies, comprising 2281 CML cases and 41000 health controls. The data demonstrated that HLA-A*11, A*74, HLA-B*40, B*47, B*55 and B*81 alleles were correlated with the increasing risk of CML. Nevertheless, HLA-DRB1*13 allele seemed to contribute to the genetic protection to CML. Conclusively we suggested that certain HLA alleles might be in association with the pathogenesis of CML in Chinese population. Due to little statistical scale, larger studies and particularly in a mono-people background, our hypothesis need to be further investigated in the future. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840597     DOI: 10.1016/j.leukres.2011.07.018

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Effects of four single nucleotide polymorphisms in microRNA-coding genes on lung cancer risk.

Authors:  Xiaohong Fan; Zhijun Wu
Journal:  Tumour Biol       Date:  2014-07-31

2.  Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis.

Authors:  Meisi Lin; Siyuan Zhang; Minyue Zhang; Jinfeng Shi; Chen Zhang; Ruifeng Luo; Jieshu You; Jiayi Sun; Jinming Zhang; Fei Gao
Journal:  Medicine (Baltimore)       Date:  2020-11-25       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.